ValiPharma
Therapeutics division with a promising cancer treatment in development.
Launch date
Market cap
€3.3m
Enterprise valuation
€3m (Public information from Sep 2024)
Share price
£0.01647 VAL.L
Company register number 05085935
Nuneaton England (HQ)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | - | <1m |
| EBITDA | (<1m) | (<1m) | (3.2m) | (1.6m) | (1.7m) | (2.9m) | (2.5m) |
| % EBITDA margin | - | - | - | - | - | - | (21295 %) |
| Profit | - | - | (2.9m) | (1.7m) | (1.8m) | (2.8m) | (2.4m) |
| % profit margin | - | - | - | - | - | - | (21226 %) |
| R&D budget | - | - | 1.2m | <1m | <1m | <1m | <1m |
| R&D % of revenue | - | - | - | - | - | - | 3993 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
N/A | Spinout | ||
N/A | Acquisition | ||
€290k | Grant | ||
| Total Funding | €290k | ||
Recent News about ValiPharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.